Picture Kenes Exhibitions Biomed Israel 2025 Tel Aviv 650x100px

Document › Details

Adaptimmune Therapeutics plc. (11/8/22). "Press Release: Adaptimmune Reports Third-Quarter Financial Results and Business Update". Philadelphia, PA & Oxford.

	Organisation	Adaptimmune Therapeutics plc (Nasdaq: ADAP)
	Group	Adaptimmune (Group)
	Organisation 2	FDA (US Food and Drug Administration)
	Group	United States (govt)
	Product	cell therapy
	Product 2	MAGE-A4 SPEAR™ T-cell therapy
	Person	Rawcliffe, Adrian (Ad) (Adaptimmune 201909– CEO joined 201503 as CFO before GSK)
	Person 2	Miller, Juli P. (Adaptimmune 201808 Director Investor Relations)

Original document
accessed by [iito] on 2022-11-18

Record changed: 2023-06-05

Picture [iito] [LSE] Life-Sciences-Europe.com Business Portal 650x200px

More documents for Adaptimmune (Group)

[1] Miltenyi Biotec B.V. & Co. KG. (9/10/24). "Press Release: Miltenyi Biotec Manufactures Lentiviral Vector for Adaptimmune’s FDA-approved TCR T-cell therapy Tecelra (afamitresgeme autoleucel)". Bergisch Gladbach....
[2] Adaptimmune Therapeutics plc. (8/1/24). "Press Release: Adaptimmune Receives U.S. FDA Accelerated Approval of TECELRA® (afamitresgene autoleucel), the First Approved Engineered Cell Therapy for a Solid Tumor". Philadeliphia, PA & Oxford....
[3] Adaptimmune Therapeutics plc. (5/30/24). "Press Release: Adaptimmune and Galapagos Sign Clinical Collaboration Agreement with an Option to Exclusively License Adaptimmune's TCR T-cell Therapy Candidate, uza-cel, in Head & Neck Cancer and Potential Future...
[4] Transgene S.A.. (1/22/24). "Press Release: Transgene Further Strengthens Management Team with Appointment of James Wentworth as Chief Business Officer". Strasbourg....
[5] Adaptimmune Therapeutics plc. (3/6/23). "Press Release: Adaptimmune and TCR2 Therapeutics Announce Strategic Combination to Create a Preeminent Cell Therapy Company for Solid Tumors". Philadeliphia, PA, Oxford & Canbridge, MA....
[6] Adaptimmune Therapeutics plc. (10/25/22). "Press Release: Adaptimmune Enhances Its Pipeline of Wholly Owned Cell Therapies for Cancer with Transfer of PRAME and NY-ESO Target Programs from GSK". Philadelphia, PA & Oxford....
[7] Adaptimmune Therapeutics plc. (1/14/20). "Press Release: Astellas and Adaptimmune Enter into Agreement to Co-Develop and Co-Commercialize Stem-Cell Derived Allogeneic CAR-T and TCR T-Cell Therapies". Tokyo, Philadelphia, PA & Oxfordshire....
[8] Adaptimmune Ltd.. (10/5/19). "Press Release: United States Orphan Drug Designation for Treatment of Soft Tissue Sarcomas Granted to SPEAR T-cells Targeting MAGE-A4". Philadeliphia, PA & Oxfordshire....
[9] Adaptimmune Ltd.. (10/1/19). "Press Release: Adaptimmune Announces Appointment of Michael Garone as Interim Chief Financial Officer". Philadeliphia, PA & Oxfordshire....
[10] Adaptimmune Ltd.. (9/30/19). "Press Release: Clear Benefit for Patients with Synovial Sarcoma Demonstrated in Updated Data from Ongoing Phase 1 Trial with ADP-A2M4 Presented at ESMO". Philadeliphia, PA & Oxfordshire....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]